Aethlon Medical (NASDAQ:AEMD) posted its quarterly earnings results on Monday. The medical equipment provider reported ($0.11) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.07) by ($0.04), Bloomberg Earnings reports.
NASDAQ:AEMD opened at $1.20 on Wednesday. Aethlon Medical has a 52 week low of $0.82 and a 52 week high of $2.04. The company has a market cap of $24.83 million, a PE ratio of -2.61 and a beta of 0.98.
A number of equities research analysts have recently commented on AEMD shares. HC Wainwright set a $3.00 price target on shares of Aethlon Medical and gave the company a “buy” rating in a report on Thursday, November 8th. ValuEngine upgraded shares of Aethlon Medical from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd.
About Aethlon Medical
Aethlon Medical, Inc, a medical device company, focuses on creating devices that address unmet medical needs in health and biodefense worldwide. The company is developing Aethlon Hemopurifier, a clinical-stage therapeutic device that eliminates life-threatening viruses from the circulatory system of infected individuals.
Read More: How to interpret a stock’s beta number
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.